150 related articles for article (PubMed ID: 8996201)
1. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
Reszka R; Beck P; Fichtner I; Hentschel M; Richter J; Kreuter J
J Pharmacol Exp Ther; 1997 Jan; 280(1):232-7. PubMed ID: 8996201
[TBL] [Abstract][Full Text] [Related]
2. Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models.
Beck P; Kreuter J; Reszka R; Fichtner I
J Microencapsul; 1993; 10(1):101-14. PubMed ID: 8445503
[TBL] [Abstract][Full Text] [Related]
3. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
[TBL] [Abstract][Full Text] [Related]
4. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice.
Shen LF; Zhang YD; Shen HJ; Zeng S; Wang X; Wang C; Le Y; Shen H
Chin Med J (Engl); 2006 Aug; 119(15):1287-93. PubMed ID: 16919188
[TBL] [Abstract][Full Text] [Related]
5. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
[TBL] [Abstract][Full Text] [Related]
6. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
Lim HJ; Masin D; Madden TD; Bally MB
J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
[TBL] [Abstract][Full Text] [Related]
7. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.
Duan Y; Xu J; Lin Y; Yu H; Gong T; Li Y; Zhang Z
J Biomed Mater Res A; 2008 Nov; 87(2):515-23. PubMed ID: 18186066
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
[TBL] [Abstract][Full Text] [Related]
9. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride].
Wang CX; Li CL; Zhao X; Yang HY; Wei N; Li YH; Zhang L; Zhang L
Yao Xue Xue Bao; 2010 Dec; 45(12):1565-9. PubMed ID: 21351498
[TBL] [Abstract][Full Text] [Related]
11. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H
J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370
[TBL] [Abstract][Full Text] [Related]
12. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
Genne P; Olsson NO; Gutierrez G; Duchamp O; Chauffert B
Anticancer Drug Des; 1994 Apr; 9(2):73-84. PubMed ID: 8166930
[TBL] [Abstract][Full Text] [Related]
13. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
[TBL] [Abstract][Full Text] [Related]
14. [Study on mitoxantrone polycyanoacrylate nanospheres].
Zhang ZR; Liao GT; Hou SX
Yao Xue Xue Bao; 1994; 29(7):544-9. PubMed ID: 7976360
[TBL] [Abstract][Full Text] [Related]
15. [Study on pharmacokinetics of mitoxantrone polycyanoacrylate nanoparticles freeze-dried injection by HPLC column switching technique].
Zhang ZR; Liao GT; Ye LM
Yao Xue Xue Bao; 1995 Nov; 30(11):843-7. PubMed ID: 8712010
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].
Chen T; Hou SX; Sun YY; Zheng Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov; 37(6):934-7. PubMed ID: 17236598
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
18. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
Li C; Cui J; Wang C; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Int J Pharm; 2008 Oct; 362(1-2):60-6. PubMed ID: 18598745
[TBL] [Abstract][Full Text] [Related]
19. Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III.
Park YS; Hakomori S; Kawa S; Ruan F; Igarashi Y
Cancer Res; 1994 Apr; 54(8):2213-7. PubMed ID: 8174128
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Schwendener RA; Fiebig HH; Berger MR; Berger DP
Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
